Abingworth raises $582m to advance late-stage clinical trials
Life sciences investment group Abingworth has raised $582m for its new clinical co-development fund to advance late-stage trials.
Deals
Pfizer acquires Amplyx Pharmaceuticals to advance anti-infectives pipeline
Pfizer has acquired US-based Amplyx Pharmaceuticals to advance its expertise in infectious disease and expand...
Science park merger creates UK’s largest life sciences ecosystem
Three companies have merged to form the UK’s first nationwide life sciences ecosystem, boosting R&D and drug discovery capacity in...
Vertex and Obsidian enter agreement to develop gene-editing treatments
Vertex Pharmaceuticals (VRTX) and Obsidian Therapeutics have entered a strategic research partnership and licensing agreement to discover and develop novel...
Janux Therapeutics raises funding to advance T cell engager treatments
Janux Therapeutics has raised $125m through a series B funding round to advance its pipeline of next-generation T cell engager...
AZ’s proposed acquisition of rare disease-focused Alexion gets US clearance
AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission (FTC) review. Cambridge-based AstraZeneca (AZ) first announced its intention to buy out…
AstraZeneca gets US clearance for proposed Alexion acquisition
The US Federal Trade Commission (FTC) has granted clearance to AstraZeneca for its proposed acquisition of Alexion Pharmaceuticals for approximately $39bn or $175 a share. The latest development comes after…
Thermo Fisher to acquire clinical research company PPD for $17.4bn
Thermo Fisher Scientific (TFS) has announced a definitive agreement to acquire clinical research organisation PPD for $47.50 per share for a total consideration of $17.4bn in cash. The company also…
Qiagen Q&A: how the COSMIC database is advancing precision oncology
When it comes to cancer drug research, the ultimate goal is to find a treatment that has both high efficacy and minimal side effects. Precision oncology, which tailors therapies to…
Tango Therapeutics to go public with $353m merger deal
Tango Therapeutics is set to go public with the signing of a definitive merger agreement with the Boxer Capital-sponsored special purpose acquisition company BCTG Acquisition worth up to a total…
Sanofi and C4X Discovery enter licensing deal worth up to €414m
Sanofi and drug discovery company C4X Discovery (C4XD) have entered an exclusive worldwide licensing agreement worth up to €414m for C4XD’s oral pre-clinical IL-17A inhibitor programme. The deal will see…
